Title:
BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/148421
Kind Code:
A1
Abstract:
Provided are bridged compounds as well as their compositions and methods of use. The compounds disclosed herein inhibit KRAS G12D activity and are useful in the treatment of various diseases including cancer.
Inventors:
JI QI (CN)
YU CHAO (CN)
WANG CE (CN)
SUN HANZI (CN)
YU CHAO (CN)
WANG CE (CN)
SUN HANZI (CN)
Application Number:
PCT/CN2022/070675
Publication Date:
July 14, 2022
Filing Date:
January 07, 2022
Export Citation:
Assignee:
BEIGENE LTD (GB)
JI QI (CN)
JI QI (CN)
International Classes:
C07D487/08; A61K31/519; A61P35/00; C07D491/04
Domestic Patent References:
| WO2021107160A1 | 2021-06-03 | |||
| WO2021219072A1 | 2021-11-04 | |||
| WO2020055756A1 | 2020-03-19 | |||
| WO2020243457A1 | 2020-12-03 |
Foreign References:
| CN109843856A | 2019-06-04 | |||
| CN111989321A | 2020-11-24 | |||
| CN112119075A | 2020-12-22 |
Other References:
DATABASE REGISTRY 23 June 2021 (2021-06-23), ANONYMOUS : "Pyrido[3,4-d]pyrimidine, 5,6,7,8-tetrahydro-7-(8-methyl-1-naphthalenyl)-2- [[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-(1-piperazinyl)- (CA INDEX NAME)", XP055949171, retrieved from STN Database accession no. 2648554-60-1
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: